6.06
2.91%
+0.12
Kala Bio Inc. stock is currently priced at $6.06, with a 24-hour trading volume of 1,120.
It has seen a +2.91% increased in the last 24 hours and a -19.29% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $6.38 pivot point. If it approaches the $5.98 support level, significant changes may occur.
Previous Close:
$6.18
Open:
$6.32
24h Volume:
1,120
Market Cap:
$17.41M
Revenue:
$5.75M
Net Income/Loss:
$-42.20M
P/E Ratio:
-86.57
EPS:
-0.07
Net Cash Flow:
$-28.54M
1W Performance:
-3.49%
1M Performance:
-19.29%
6M Performance:
-13.94%
1Y Performance:
-57.54%
Kala Bio Inc. Stock (KALA) Company Profile
Name
Kala Bio Inc.
Sector
Industry
Phone
781 996 5252
Address
1167 Massachusetts Avenue, Arlington, MA
Kala Bio Inc. Stock (KALA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
Jul-23-20 | Initiated | Northland Capital | Outperform |
Jun-01-20 | Resumed | Oppenheimer | Outperform |
May-27-20 | Reiterated | H.C. Wainwright | Buy |
Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc. Stock (KALA) Latest News
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
Zacks Investment Research
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
GlobeNewswire Inc.
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
Kala Bio Inc. Stock (KALA) Financials Data
Kala Bio Inc. (KALA) Revenue 2024
KALA reported a revenue (TTM) of $5.75 million for the quarter ending September 30, 2022, a -50.54% decline year-over-year.
Kala Bio Inc. (KALA) Net Income 2024
KALA net income (TTM) was -$42.20 million for the quarter ending December 31, 2023, a +5.85% increase year-over-year.
Kala Bio Inc. (KALA) Cash Flow 2024
KALA recorded a free cash flow (TTM) of -$28.54 million for the quarter ending December 31, 2023, a +63.98% increase year-over-year.
Kala Bio Inc. (KALA) Earnings per Share 2024
KALA earnings per share (TTM) was -$17.75 for the quarter ending December 31, 2023, a +40.48% growth year-over-year.
Kala Bio Inc. Stock (KALA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Brazzell Romulus K | SEE REMARKS |
Jan 04 '24 |
Sale |
6.74 |
1,617 |
10,899 |
91,473 |
Kharabi Darius | CHIEF BUSINESS OFFICER |
Jan 04 '24 |
Sale |
6.73 |
1,385 |
9,321 |
65,117 |
Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jan 04 '24 |
Sale |
6.74 |
1,227 |
8,270 |
66,136 |
Trachtenberg Eric | SEE REMARKS |
Jan 04 '24 |
Sale |
6.74 |
1,227 |
8,270 |
68,066 |
About Kala Bio Inc.
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
Cap:
|
Volume (24h):